EP Patent

EP1216699A1 — Transdermalsystem enthaltend ein hochpotentes Gestagen

Assigned to Bayer Pharma AG · Expires 2002-06-26 · 24y expired

What this patent protects

Transdermalsystem gekennzeichnet durch einen Gehalt an (21S)-21-Hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-trien-3,20-dion.

USPTO Abstract

Transdermalsystem gekennzeichnet durch einen Gehalt an (21S)-21-Hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-trien-3,20-dion.

Drugs covered by this patent

Patent Metadata

Patent number
EP1216699A1
Jurisdiction
EP
Classification
—
Expires
2002-06-26
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.